{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:51:31Z","timestamp":1794959491302,"version":"4.9.1"},"reference-count":151,"publisher":"Annual Reviews","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:p>The liver plays a central role in regulating lipid and glucose metabolism, particularly in transitioning between energy storage and provision in fed and fasting states. Loss of metabolic flexibility, characterized by the impaired capacity to shift between different energy substrates, sets the stage for accumulation of hepatic triglyceride as lipid droplets and further metabolic perturbations. Cross talk between the liver and other organs, including adipose tissue, pancreas, and muscle, is relevant in this transition. In addition to the metabolic consequences of steatosis, there are significant liver risks related to triggered inflammatory and fibrotic processes. Steatotic liver diseases affect an estimated one in three adults globally and contribute to substantial morbidity and mortality. This review focuses on the liver's role in lipid metabolism, defining metabolic health and unhealth, the pathogenic underpinnings that lead to steatohepatitis and hepatic fibrosis, and the clinical features and therapies for the most common forms of steatotic liver diseases.<\/jats:p>","DOI":"10.1146\/annurev-physiol-022724-105515","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:40:52Z","timestamp":1752853252000},"page":"325-352","source":"Crossref","is-referenced-by-count":31,"title":["At the Crossroads of Health and Disease: Consequences of Fat in the Liver"],"prefix":"10.1146","volume":"87","author":[{"given":"Matthew","family":"Dukewich","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA; email:\u00a0Terrault@usc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA; email:\u00a0Terrault@usc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA; email:\u00a0Terrault@usc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/apt.17958","article-title":"Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population","volume":"59","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","year":"2023","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1101\/gad.891301","article-title":"SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation","volume":"15","year":"2001","journal-title":"Genes Dev"},{"key":"B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice","volume":"59","year":"2018","journal-title":"J. Lipid Res."},{"key":"B5","article-title":"The role of liver X receptor in hepatic de novo lipogenesis and cross-talk with insulin and glucose signaling","volume-title":"Lipid Metabolism","year":"2013"},{"key":"B6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41594-021-00718-y","article-title":"Seipin forms a flexible cage at lipid droplet formation sites","volume":"29","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1074\/jbc.M109.064501","article-title":"A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis","volume":"285","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1172\/JCI65179","article-title":"Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis","volume":"122","year":"2012","journal-title":"J. Clin. Investig."},{"key":"B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","article-title":"Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1210\/jcem.87.7.8638","article-title":"Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men","volume":"87","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","year":"2001","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","year":"2009","journal-title":"PNAS"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/biom11020222","article-title":"The role of cardiolipin as a scaffold mitochondrial phospholipid in autophagosome formation: in vitro evidence","volume":"11","year":"2021","journal-title":"Biomolecules"},{"key":"B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-nutr-071816-064836","article-title":"Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues","volume":"37","year":"2017","journal-title":"Annu. Rev. Nutr."},{"key":"B18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","year":"2010","journal-title":"J. Hepatol."},{"key":"B19","first-page":"539426","article-title":"Health implications of high dietary omega-6 polyunsaturated fatty acids","year":"2012","journal-title":"J. Nutr. Metab."},{"key":"B20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","article-title":"Ceramides in metabolism: key lipotoxic players","volume":"83","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"G300","DOI":"10.1152\/ajpgi.00222.2016","article-title":"Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis","volume":"312","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.redox.2017.08.022","article-title":"The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading","volume":"14","year":"2018","journal-title":"Redox. Biol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cell.2018.08.020","article-title":"ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P","volume":"175","year":"2018","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"B25","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","year":"2012","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"crossref","first-page":"26591","DOI":"10.1074\/jbc.M109.022491","article-title":"JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis","volume":"284","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1074\/jbc.M510660200","article-title":"Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis","volume":"281","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","year":"2013","journal-title":"J. Hepatol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1172\/JCI27726","article-title":"TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality","volume":"116","year":"2006","journal-title":"J. Clin. Investig."},{"key":"B31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2015.01.032","article-title":"Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity","volume":"62","year":"2015","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","year":"2018","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","year":"2017","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1042\/CS20140732","article-title":"Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis","volume":"129","year":"2015","journal-title":"Clin. Sci."},{"key":"B36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jhep.2019.11.008","article-title":"Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease","volume":"72","year":"2020","journal-title":"J. Hepatol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.28676","article-title":"Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/hepr.12282","article-title":"Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease","volume":"44","year":"2014","journal-title":"Hepatol. Res."},{"key":"B39","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/acer.14041","article-title":"Decreased macrophage autophagy promotes liver injury and inflammation from alcohol","volume":"43","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"B40","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/ng.921","article-title":"Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci","volume":"43","year":"2011","journal-title":"Nat. Genet."},{"key":"B41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1073\/pnas.1422590112","article-title":"Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides","volume":"112","year":"2015","journal-title":"PNAS"},{"key":"B42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(99)80033-6","article-title":"Mitochondrial abnormalities in non-alcoholic steatohepatitis","volume":"31","year":"1999","journal-title":"J. Hepatol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1074\/jbc.M706666200","article-title":"Loss of macroautophagy promotes or prevents fibroblast apoptosis depending on the death stimulus","volume":"283","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ncb1482","article-title":"Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis","volume":"8","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"B45","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","article-title":"Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy","volume":"122","year":"2005","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","year":"2023","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"crossref","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","year":"2017","journal-title":"PLOS ONE"},{"key":"B51","first-page":"e0251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","year":"2021","journal-title":"J. Hepatol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"B54","first-page":"e0352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","year":"2024","journal-title":"Hepatol. Commun."},{"key":"B55","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort","volume":"70","year":"2021","journal-title":"Gut"},{"key":"B56","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"B57","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"B59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/liv.14749","article-title":"Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis","volume":"41","year":"2021","journal-title":"Liver Int"},{"key":"B61","doi-asserted-by":"crossref","first-page":"1244405","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies","volume":"101","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B64","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","year":"2023","journal-title":"Hepatology"},{"key":"B65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"B66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ecl.2023.01.006","article-title":"A bidirectional association between obstructive sleep apnea and metabolic-associated fatty liver disease","volume":"52","year":"2023","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"B68","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"B69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1478-3231.2011.02637.x","article-title":"Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients","volume":"32","year":"2012","journal-title":"Liver Int"},{"key":"B70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"B71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cen.14344","article-title":"Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease","volume":"94","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"B72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5604\/01.3001.0009.8593","article-title":"Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"16","year":"2017","journal-title":"Ann. Hepatol."},{"key":"B73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.28514","article-title":"A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"B74","doi-asserted-by":"crossref","first-page":"e1002542","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database","volume":"15","year":"2018","journal-title":"PLOS Med"},{"key":"B75","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","year":"2020","journal-title":"J. Hepatol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"e222695","DOI":"10.1148\/radiol.222695","article-title":"Diagnosis and monitoring of nonalcoholic steatohepatitis: current state and future directions","volume":"310","year":"2024","journal-title":"Radiology"},{"key":"B77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B78","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","article-title":"Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD","volume":"19","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B79","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","year":"2023","journal-title":"Nat. Med."},{"key":"B80","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"B81","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort","volume":"20","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B82","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.32207","article-title":"High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population","volume":"75","year":"2022","journal-title":"Hepatology"},{"key":"B83","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","year":"2019","journal-title":"Clin. Nutr."},{"key":"B85","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajg.2010.488","article-title":"Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease","volume":"106","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B86","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s10620-022-07779-z","article-title":"High-intensity interval training is safe, feasible and efficacious in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"68","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"B87","doi-asserted-by":"crossref","first-page":"e13659","DOI":"10.1111\/eci.13659","article-title":"Is there an \u2018ideal\u2019 diet for patients with NAFLD?","volume":"52","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"B88","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"B89","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/nu9080870","article-title":"Effect of Mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study","volume":"9","year":"2017","journal-title":"Nutrients"},{"key":"B90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12876-019-1132-8","article-title":"Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial","volume":"19","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"B91","first-page":"94","article-title":"The impact of Ramadan fasting on fatty liver disease severity: a retrospective case control study from Israel","volume":"23","year":"2021","journal-title":"Isr. Med. Assoc. J."},{"key":"B92","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/07315724.2017.1339644","article-title":"The effects of Ramadan fasting on body composition, blood pressure, glucose metabolism, and markers of inflammation in NAFLD patients: an observational trial","volume":"36","year":"2017","journal-title":"J. Am. Coll. Nutr."},{"key":"B93","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"B94","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1530\/EC-18-0499","article-title":"Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis","volume":"7","year":"2018","journal-title":"Endocr. Connect."},{"key":"B96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"B97","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B98","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"B100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"B101","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B102","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"B103","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B106","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"B107","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B108","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"B109","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"B110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7150\/ijbs.87305","article-title":"The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"20","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"B111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B112","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B113","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","year":"2021","journal-title":"Hepatology"},{"key":"B114","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","year":"2023","journal-title":"Nat. Med"},{"key":"B115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"B116","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"B117","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","year":"2024","journal-title":"Hepatology"},{"key":"B118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B119","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B122","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B123","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","year":"2021","journal-title":"Hepatology"},{"key":"B124","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","year":"2022","journal-title":"J. Hepatol."},{"key":"B125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","year":"2020","journal-title":"J. Hepatol."},{"key":"B126","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B127","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"B128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B129","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.510230513","article-title":"Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"B130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJM199001113220205","article-title":"High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism","volume":"322","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B132","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","year":"2024","journal-title":"Hepatology"},{"key":"B133","doi-asserted-by":"crossref","first-page":"e2347548","DOI":"10.1001\/jamanetworkopen.2023.47548","article-title":"Alcohol intake thresholds among individuals with steatotic liver disease","volume":"6","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B134","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/liv.15849","article-title":"Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease","volume":"44","year":"2024","journal-title":"Liver Int"},{"key":"B135","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2468-1253(21)00430-1","article-title":"Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B136","doi-asserted-by":"crossref","first-page":"9915","DOI":"10.1074\/jbc.M112.434910","article-title":"Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core","volume":"288","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B137","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00705-013-1892-3","article-title":"Hepatitis C virus nonstructural protein 5A favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome","volume":"159","year":"2014","journal-title":"Arch. Virol."},{"key":"B138","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1074\/jbc.M115.694059","article-title":"The hepatitis C virus-induced NLRP3 inflammasome activates the sterol regulatory element-binding protein (SREBP) and regulates lipid metabolism","volume":"291","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B139","article-title":"Hepatitis C virus infection induces hepatic expression of NF-\u03baB-inducing kinase and lipogenesis by downregulating miR-122","volume":"10","year":"2019","journal-title":"mBio"},{"key":"B140","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"B141","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/jhep.2002.36370","article-title":"Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"B142","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/liv.15876","article-title":"Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: a systematic review","volume":"44","year":"2024","journal-title":"Liver Int"},{"key":"B143","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy","volume":"13","year":"2021","journal-title":"Viruses"},{"key":"B144","first-page":"6825493","article-title":"HIV as a cause of immune activation and immunosenescence","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B145","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/cells10010174","article-title":"The impact of HIV- and ART-induced mitochondrial dysfunction in cellular senescence and aging","volume":"10","year":"2021","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"crossref","first-page":"e26072","DOI":"10.1002\/jia2.26072","article-title":"Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa","volume":"26","year":"2023","journal-title":"J. Int. AIDS Soc."},{"key":"B147","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/HEP.0000000000000313","article-title":"Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study","volume":"78","year":"2023","journal-title":"Hepatology"},{"key":"B148","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","article-title":"Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis","volume":"21","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B149","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/cid\/ciaa382","article-title":"Clinical predictors of liver fibrosis presence and progression in human immunodeficiency virus-associated nonalcoholic fatty liver disease","volume":"72","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B150","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/cid\/ciz435","article-title":"Natural course of nonalcoholic fatty liver disease and type 2 diabetes in patients with human immunodeficiency virus with and without combination antiretroviral therapy-associated lipodystrophy: a 16-year follow-up study","volume":"70","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B151","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial","volume":"6","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Annual Review of Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-physiol-022724-105515?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:01:53Z","timestamp":1773460913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-physiol-022724-105515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1146\/annurev-physiol-022724-105515","relation":{},"ISSN":["0066-4278","1545-1585"],"issn-type":[{"value":"0066-4278","type":"print"},{"value":"1545-1585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}